Company: CDT
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-024140
Chunk: 124

Company: CDT Equity Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 8
Chunk 124
---

    2024 
  
    Operating expenses: 

    Research & development expenses-clinical asset development 
    $222  
    $25  
    $411  
    $153 
  
    Research & development expense – related parties 
     1,638  
     -  
     2,365  
     - 
  
    General and administrative expenses – legal & professional fees 
     872  
     711  
     1,632  
     956 
  
    General and administrative expenses – accounting & audit fees 
     378  
     256  
     922  
     903 
  
    General and administrative expenses – salaries, payroll and SBC 
     751  
     1,184  
     1,444  
     2,170 
  
    General and administrative expenses - other 
     1,091  
     964  
     1,794  
     1,913 
  
    Total operating costs and expenses 
     4,952  
     3,140  
     8,568  
     6,095 
  
    Operating loss 
     (4,952) 
     (3,140) 
     (8,568) 
     (6,095)
  
    Other income (expenses): 

    Other income (expense), net 
     (1,023) 
     (2,126) 
     (1,992) 
     (2,613)
  
    Interest Income 
     4  
     2  
     12  
     11 
  
    Interest expense, net 
     (57) 
     (119) 
     (233) 
     (238)
  
    Total other (expense) income, net 
     (1,076) 
     (2,243) 
     (2,213) 
     (2,840)
  
    Net loss 
    $(6,028) 
    $(5,383) 
    $(10,781) 
     (8,935)

Other
segment items consist of the items within Note 12 to the condensed consolidated financial statements.

16.
Subsequent Events

Sarborg
- Additional Agreement Addendum

On
July 1, 2025 the Company entered into an Addendum